Breast Cancer Treatment in India for CIS & Africa Women: Surgery, Chemo & Complete 2026 Guide

Breast cancer is the most diagnosed cancer in women globally—and this burden is felt acutely by women in Kazakhstan, Russia, Uzbekistan, Nigeria, and Ghana. According to GLOBOCAN 2022, breast cancer is the leading cancer in women across these countries, accounting for approximately 22–28% of all new female cancer diagnoses. Yet the experience of breast cancer in CIS and African countries differs significantly from high-income countries: later-stage diagnosis, limited access to HER2-targeted therapy, restricted radiotherapy capacity, and significantly higher out-of-pocket costs for treatment in private settings.

This guide is written for women in Russia, Kazakhstan, Uzbekistan, Nigeria, Ghana, Kenya, and Uganda who have been diagnosed with breast cancer and are evaluating India as a treatment destination. It covers every aspect: staging, surgical options, chemotherapy protocols, targeted therapy for HER2-positive disease, triple-negative breast cancer, reconstruction, and what the entire journey looks like via MediKaya Healthcare.

Understanding Your Breast Cancer Diagnosis — The Essential Terms

Hormone Receptor Status (ER/PR)

Oestrogen receptor (ER) and progesterone receptor (PR) status tells oncologists whether the cancer grows in response to female hormones. ER+/PR+ cancers — the most common type — respond well to hormone-blocking therapies (Tamoxifen for pre-menopausal women, Aromatase Inhibitors for post-menopausal women) which are highly affordable in India.

HER2 Status

HER2 (human epidermal growth factor receptor 2) is overexpressed in approximately 15–20% of breast cancers. HER2-positive breast cancer was historically one of the most aggressive subtypes, but targeted therapy with Trastuzumab (Herceptin) has transformed outcomes — HER2+ breast cancer treated with trastuzumab now has better outcomes than many HER2-negative cancers. Critically, generic Trastuzumab biosimilars manufactured by Indian companies are available in India at $1,500–$3,000 per month — compared to $8,000–$15,000 per month for branded Herceptin in Western countries. This price difference is life-changing for patients from Nigeria and Kazakhstan.

Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer — ER negative, PR negative, HER2 negative — does not respond to hormone therapy or trastuzumab. It requires chemotherapy as the backbone of treatment, often combined with immunotherapy (Pembrolizumab for PDL1-positive TNBC) or PARP inhibitors (for BRCA-mutated TNBC). India’s major cancer centres are experienced with all of these regimens, and generic versions of Pembrolizumab are now available in India, making immunotherapy for TNBC accessible at significantly reduced cost.

Breast Cancer Surgery Options in India — Lumpectomy vs Mastectomy

The choice between breast-conserving surgery (lumpectomy) and mastectomy depends on tumour size relative to breast size, tumour location, BRCA status, and patient preference. India’s oncology centres offer both approaches, with reconstruction options discussed at initial consultation.

Lumpectomy (Breast-Conserving Surgery)

Lumpectomy removes the tumour with a margin of surrounding healthy tissue, preserving the breast. It is appropriate for most Stage 1 and Stage 2 cancers and for patients who respond well to neoadjuvant chemotherapy (chemo given before surgery to shrink the tumour). Lumpectomy is followed by radiation therapy to the remaining breast tissue. Cost in India: $3,000–$4,500 for surgery + $3,500–$5,000 for radiation = $6,500–$9,500 total local treatment.

Mastectomy (Complete Breast Removal)

Mastectomy is appropriate for larger tumours, multifocal disease, BRCA1/2 mutation carriers, or patient preference. Skin-sparing and nipple-sparing mastectomy techniques are available at Apollo Athena and BLK-Max, preserving the natural breast envelope for better reconstruction outcomes. Cost of mastectomy in India: $4,000–$6,500.

Breast Reconstruction

Immediate or delayed breast reconstruction is available at Apollo Athena Women’s Cancer Centre. Options include implant-based reconstruction and autologous reconstruction (using the patient’s own tissue — TRAM flap, DIEP flap). The choice depends on body habitus, radiation plan, and patient preference. Many patients from CIS and Africa choose to have primary surgery in India and then consider reconstruction in a subsequent trip or locally if available.

Chemotherapy for Breast Cancer in India — Protocols and Costs

Chemotherapy for breast cancer is given in cycles — typically every 3 weeks. The specific regimen depends on tumour subtype, stage, and risk factors. India’s major cancer centres follow NCCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) guidelines — the same guidelines used in the USA and Europe.

Important: Many patients from CIS countries and Africa fly to India for the initial treatment planning and first 1–2 cycles, then return home for subsequent cycles if a local oncologist can administer the same protocol. MediKaya coordinates the treatment protocol handover to the local oncologist with a detailed written protocol in both English and Russian.

Apollo Athena Women’s Cancer Centre — MediKaya Healthcare Primary Partner

Apollo Athena Women’s Cancer Centre in Delhi is India’s first dedicated women’s cancer center and MediKaya’s primary partner for breast cancer and gynecological cancer treatment. The center is led by Prof. Dr. Geeta Kadayaprath, who trained at MD Anderson Cancer Center in Houston—consistently ranked the world’s top cancer hospital.

• Dedicated breast cancer multidisciplinary team: surgeon, oncologist, radiation oncologist, genetic counsellor, reconstructive surgeon
• Robotic breast surgery available
• Genetic testing: BRCA1/BRCA2 testing available for high-risk patients
• Fertility preservation consultation for pre-menopausal patients before chemotherapy
• International patients: English-speaking team; MediKaya patients receive consultation within 48 hours
• NABH and JCI accredited

Breast Cancer for CIS Women—Kazakhstan and Russia Context

In Kazakhstan, breast cancer accounts for approximately 22% of all new female cancer cases and is the second leading cause of cancer death in women after cervical cancer. Mammography screening programmes exist but coverage in rural Kazakhstan is limited. In Russia, breast cancer is the most common cancer in women, with relatively well-developed treatment infrastructure — but significant variation in access to HER2-targeted therapy in state hospitals and waiting times for surgery in major cities.

For Kazakhstani and Russian women with HER2-positive breast cancer or triple-negative breast cancer requiring Pembrolizumab, India offers access to generic targeted therapies at a fraction of the private sector cost in Russia or Kazakhstan. Many patients use India for the specialised treatment (surgery, targeted therapy) and then transition to local oncologists for ongoing monitoring under the protocol MediKaya provides.

Breast Cancer for African Women — Nigeria, Ghana, Kenya Context

Nigeria and Ghana have among the world’s highest rates of triple-negative breast cancer — a biologically aggressive subtype that is more common in women of West African ancestry. This fact has important treatment implications: TNBC does not respond to hormone therapy (Tamoxifen) or Herceptin, requiring chemotherapy as the primary systemic treatment. The addition of Pembrolizumab immunotherapy for PDL1-positive TNBC (KEYNOTE-522 protocol) has significantly improved outcomes — and generic Pembrolizumab is now available in India, making this breakthrough treatment accessible for African patients.

Frequently Asked Questions — Breast Cancer India CIS and Africa